Department of Clinical Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.
Lab Med. 2023 May 2;54(3):270-281. doi: 10.1093/labmed/lmac094.
Based on the current difficulties in early diagnosis of HBV-related hepatocellular carcinoma (HBV-HCC), we assessed the values of preoperative serum fibrinogen-like protein 1 (FGL1) by itself and in combination with alpha-fetoprotein (AFP) for the diagnosis of HBV-HCC.
We used ELISA and chemiluminescence assays to detect the serum levels of FGL1 and AFP, respectively.
Serum FGL1 level in the HBV-HCC group was significantly higher than in the chronic HBV (CHBV) group, the liver cirrhosis (LC) group, and the healthy control (HC) group. Serum FGL1 had an outstanding performance in distinguishing AFP-negative HBV-HCC from different control conditions. In the patients with AFP-negative HBV-HCC, the sensitivity of serum FGL1 was high. Moreover, serum FGL1 had a stronger performance than AFP in distinguishing early-stage HBV-HCC.
Serum FGL1 is significantly elevated among patients with HBV-HCC, including those with negative AFP and with disease at an early stage. Hence, serum FGL1 may serve as a potential diagnostic marker in the early diagnosis of HBV-HCC.
基于乙型肝炎病毒相关性肝细胞癌（HBV-HCC）早期诊断的当前困难，我们评估了术前血清纤维蛋白原样蛋白 1（FGL1）单独及其与甲胎蛋白（AFP）联合用于诊断 HBV-HCC 的价值。
我们分别使用 ELISA 和化学发光测定法检测血清 FGL1 和 AFP 水平。
HBV-HCC 组血清 FGL1 水平显著高于慢性乙型肝炎（CHBV）组、肝硬化（LC）组和健康对照组（HC）。血清 FGL1 在鉴别 AFP 阴性 HBV-HCC 与不同对照条件方面表现出色。在 AFP 阴性的 HBV-HCC 患者中，血清 FGL1 的灵敏度较高。此外，血清 FGL1 在鉴别早期 HBV-HCC 方面的表现优于 AFP。
HBV-HCC 患者，包括 AFP 阴性和疾病早期患者，血清 FGL1 显著升高。因此，血清 FGL1 可能成为 HBV-HCC 早期诊断的潜在诊断标志物。
